Clinical effect of fudosteine in the treatment of patients with chronic obstructive pulmonary disease with pulmonary fibrosis
Objective To analyze the clinical effect of fudosteine in the treatment of chronic obstructive pulmonary disease(COPD)with pulmonary fibrosis.Methods Sixty patients with COPD and pulmonary fibrosis admitted in our hospital from January 2019 to January 2020 were selected and divided into control group and observation group according to different treatment methods,with 30 cases in each group.The control group was treated with acetylcysteine,and the observation group was treated with fudosteine on the basis of the control group.The pulmonary function,pulmonary fibrosis indexes and serological indexes were compared between the two groups before treatment and after 6 and 9 months of treatment.Results After 6 and 9 months of treatment,the forced expiratory volume in one second(FEV1)and forced vital capacity(FVC)in the observation group were higher than those in the control group(P＜0.05).After 6 and 9 months of treatment,the levels of serum hyaluronic acid(HA),laminin(LN),interleukin-8(IL-8),intercellular cell adhesion molecule-1(ICAM-1),krebs von den lungen-6(KL-6),transforming growth factor-β1(TGF-β1)and chemokine CXC ligand 13(CXCL13)in the observation group were lower than those in the control group(P＜0.05).Conclusion Fordosteine in the treatment of COPD patients with pulmonary fibrosis can strengthen pulmonary function,relieve pulmonary fibrosis,and regulate serum factor levels,which is worth of promotion and application.
chronic obstructive pulmonary diseasepulmonary fibrosisfudosteineacetylcysteinepulmonary function
NETL
NSTL
万方数据
